Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

Medicare Part B covers Leqembi for people with early Alzheimer's or mild cognitive impairment. Learn more about Leqembi and Medicare coverage here.

The WVU Rockefeller Neuroscience Institute (RNI) is providing patients greater statewide and regional access to a ...

Biogen faces potential earnings drop of 20-30% by 2030 due to Ocrevus biosimilar competition. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030.

The federal Food & Drug Administration has approved two new Alzheimer’s medications that can offer people more time to live ...

Eisai has recently made headlines with the approval of LEQEMBI in Mexico for early Alzheimer's treatment, marking a significant step in its global expansion strategy. Despite facing challenges such as ...

What time is it?” Cheryl Miller asks her husband, John. He wants to answer, but his wife has already asked him that question ...

While there's no cure yet for Alzheimer's, researchers are finally making more progress in better understanding the disease ...

Recent discussions at an Institute for Value-Based Medicine event highlighted the significant potential of biosimilars in ...